drugset / Trial / NCT00693316

Safety and Tolerability Study With Single Ascending Doses of ORM-12741

NCT00693316 ↗

Phase 1 Completed 120 enrolled Orion Corporation, Orion Pharma
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of escalating doses of ORM-12741 in healthy volunteers.

Timeline

Start
2008-07
Primary completion
2009-10
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Subject ORM-12741 Small molecule — —

Indications

No indication recorded.